Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 86

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 86
---
 each Supporting Person has agreed, among other things, to vote its NLS Common Shares, and any other voting securities such Supporting Person might hold, in favor of (A) (i) the issuance of NLS Common Shares equal to the required number of NLS Common Shares to serve as the Merger Consideration, and (ii) an ordinary capital increase under Swiss law, excluding the subscription rights of the existing holders of NLS Common Shares, for the purpose of making available the required number of NLS Common Shares to serve as the Merger Consideration, and (B) any proposal to adjourn or postpone the NLS Meeting to a later date if there are not sufficient votes to approve resolutions (A)(i) and (ii). Kadimastem and certain shareholders also entered into voting and support agreements. The Merger has been approved by the shareholders of Kadimastem. Executive Officers of NLS Following the Merger (Page 180) Immediately following the Merger, subject to the approval of NLS shareholders, the executive officers’ team of NLS is expected to be composed as set forth below:

| Name                        |     | Age |     | Position(s) with NLS                                   |     | Current Position(s)                                          |
| Ronen Twito                 |     |  50 |     | Executive Chairman nominee and Chief Executive Officer |     | Executive Chairman and Chief Executive Officer of Kadimastem |
| Prof. Michel Revel, MD, PhD |     |  86 |     | Director and Chief Scientific Officer                  |     | Director and Chief Scientific Officer of Kadimastem          |
| Kfir Molakandov PhD         |     |  47 |     | Vice President of Research and Development             |     | Vice President of Research and Development of Kadimastem     |
| Nicole Fernandez-McGovern   |     |  51 |     | Chief Financial Officer                                |     | Chief Financial Officer of NLS                               |
| Ariel Revel, MD             |     |  63 |     | Director of Medical Affairs                            |     | Director of Medical Affairs of Kadimastem                    |

Directors of NLS Following the Merger (Page 180) At and immediately after the Effective Time of the Merger, the NLS Board is expected to be composed of the individuals set forth in the table below. The directors shall serve until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal.

| Name                        |     | Age |